Literature DB >> 31247194

Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring.

Diarmaid J Murphy1, Clare F McCoy1, Marlena Plagianos2, Saumya RamaRao2, Ruth Merkatz2, Heather Clark2, Peter Boyd1, Bruce Variano2, R Karl Malcolm3.   

Abstract

OBJECTIVES: The primary aim was to investigate post-use ring weight as a potential measure of cumulative adherence to a progesterone-releasing vaginal ring. STUDY
DESIGN: We weighed and quantified residual progesterone in 115 vaginal rings following 90-day use by participants in an acceptability trial conducted in Nigeria, Senegal and Kenya. The primary objective was to correlate residual progesterone content with post-use ring weight. Secondary objectives included correlating ring weight with putative duration of ring use, and, where participants used two rings consecutively in the study, correlating residual content between these paired rings.
RESULTS: Mean ring weight and progesterone content of used rings was 8.62±0.24 g and 1245±245 mg respectively, versus 9.37±0.02 and 2058±21 mg for control rings. Most used rings (90.4%) had residual progesterone levels less than 85% of the nominal loading. Linear regression showed a strong positive linear trend between residual progesterone content and post-use ring weight for all rings (r2=0.82). Duration of ring use was inversely associated (p=.00020) with ring weight.
CONCLUSIONS: Post-use ring weight is highly correlated with residual progesterone content, a benchmark objective cumulative measure of adherence, and thus potentially useful as a surrogate objective measure of cumulative adherence to a progesterone-releasing vaginal ring. IMPLICATION STATEMENT: For vaginal rings containing a high initial drug loading and releasing a relatively large fraction of the initial loading during clinical use, post-use ring weight may offer a simple and inexpensive alternative to residual content testing for accurate monitoring of user adherence.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; Contraceptive vaginal ring; HIV microbicide; Progesterone; User adherence

Year:  2019        PMID: 31247194     DOI: 10.1016/j.contraception.2019.06.013

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Color, Scent and Size: Exploring Women's Preferences Around Design Characteristics of Drug-Releasing Vaginal Rings.

Authors:  Xinyu Zhao; Cecilia Milford; Jenni Smit; Bongiwe Zulu; Peter Boyd; R Karl Malcolm; Mags Beksinska
Journal:  AIDS Behav       Date:  2022-03-16

Review 2.  The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings.

Authors:  Louise Carson; Ruth Merkatz; Elena Martinelli; Peter Boyd; Bruce Variano; Teresa Sallent; Robert Karl Malcolm
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.